NCHR Testimony at FDA Meeting on Pediatric Cancer Drugs

June 21, 2017. Drug efficacy is a complex issue for children with chronic and/or rare diseases like the cancers discussed here. We commend the FDA and this committee for providing an open discussion focused on the best ways to test these five new drugs in pediatric populations. This marks a positive effort to help ensure that drugs are safe and effective for everyone for whom they are prescribed, particularly when the cost of these drugs can be so high.

Read More »
Page 30 of 109« First...1020...2829303132...405060...Last »